Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 5/2010

01-10-2010

Interstitial Lung Disease in Rheumatoid Arthritis

Author: Dana P. Ascherman

Published in: Current Rheumatology Reports | Issue 5/2010

Login to get access

Abstract

Rheumatoid arthritis (RA) is the most common systemic autoimmune disease in the United States, affecting 1% to 2% of the adult population. Although joints and synovium are the primary targets in this disorder, extra-articular manifestations involving the lungs can lead to significant morbidity and excess mortality. Among the various pulmonary complications that occur in RA, interstitial lung disease (ILD) is the most damaging, with effects ranging from subclinical inflammation/scarring to end-stage pulmonary fibrosis. New insights during the past several years have underscored the epidemiologic impact of clinically/functionally significant RA-associated ILD (RA-ILD) and have begun to identify factors contributing to the pathogenesis of this potentially devastating complication of RA. Despite these advancements, the complexity of RA-ILD and the lack of reliable predictors for disease progression highlight the need for improved biomarker development. Establishing such detailed molecular signatures will ultimately guide the application and timing of therapeutic agents that include immunomodulators as well as newly studied antifibrotic agents.
Literature
1.
Nannini C, Ryu JH, Matteson EL: Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:340–346.CrossRefPubMed
2.
Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003, 48:917–926.CrossRefPubMed
3.
4.
•• Gochuico BR, Avila NA, Chow CK, et al.: Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168:159–166. Through the use of multiplex ELISA-based technology, this study examined the relationship between levels of various cytokines/chemokines in bronchoalveolar lavage fluid and subtype of RA-ILD, demonstrating that specific cytokine profiles predict radiographic progression in “subclinical” RA-ILD.CrossRefPubMed
5.
Metafratzi ZM, Georgiadis AN, Ioannidou CV, et al.: Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007, 36:338–344.CrossRefPubMed
6.
Young A, Koduri G, Batley M, et al.: Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46:350–357.CrossRef
7.
Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, et al.: Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 2006, 25:213–218.CrossRefPubMed
8.
Cortet B, Flipo RM, Remy-Jardin M, et al.: Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54:815–819.CrossRefPubMed
9.
Demir R, Bodur H, Tokoglu F, et al.: High resolution computed tomography of the lungs in patients with rheumatoid arthritis. Rheumatol Int 1999, 19:19–22.CrossRefPubMed
10.
Gabbay E, Tarala R, Will R, et al.: Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997, 156:528–535.PubMed
11.
Georgiadis AN, Metafratzi ZM, Drosos AA: Pulmonary abnormalities in patients with early and longstanding rheumatoid arthritis. J Rheumatol 2009, 36:444–445; author reply 445–446.CrossRefPubMed
12.
• Kelly C, Saravanan V: Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 2008, 9:3221–3230. In addition to reviewing therapeutic approaches for RA-ILD, this article further defines the radiographic, histopathologic, and epidemiologic characteristics of this extra-articular complication.CrossRefPubMed
13.
•• Kim EJ, Elicker BM, Maldonado F, et al.: Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35:1322–1328. This study suggests that UIP is the most common subtype of RA-ILD, with a poor prognosis paralleling that of IPF.CrossRefPubMed
14.
•• Mori S, Cho I, Koga Y, Sugimoto M: Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008, 35:1513–1521. This prospective study of 126 patients with early and late RA demonstrates significant rates of specific HRCT abnormalities that define radiographic categories corresponding to NSIP, UIP, cryptogenic organizing pneumonia, and bronchiolitis. Equally important, these radiographically defined subtypes are associated with characteristic pulmonary function test abnormalities.PubMed
15.
Tanaka N, Kim JS, Newell JD, et al.: Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004, 232:81–91.CrossRefPubMed
16.
• Koduri G, Norton S, Young A, et al.: Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010 Mar 11 (Epub ahead of print). In this large inception cohort of patients with RA observed for up to 20 years (median follow-up period, 10 years), the authors determined that the annualized incidence of clinically evident RA-ILD was 4.1 per 1000 people. More significantly, this study indicates that the mortality rate among patients with clinically evident RA-ILD is greater than 50%, with a median survival of 3 years.
17.
•• Bongartz T, Nannini C, Medina-Velasquez YF, et al.: Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population based study. Arthritis Rheum 2010, 62:1583–1591. This important population-based study from Olmstead County, MN, provides a detailed quantitative analysis of mortality attributable to RA-ILD, indicating that the percent of excess mortality in RA due to ILD is comparable to rates associated with congestive heart failure. The authors also demonstrate that older age, male gender, and increased articular disease severity correlate with the development of RA-ILD.CrossRefPubMed
18.
• Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM: Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009, 33:882–896. This review evaluates the radiographic incidence of RA-ILD and the impact of this pulmonary complication on mortality in RA.CrossRefPubMed
19.
Dawson JK, Fewins HE, Desmond J, et al.: Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61:517–521.CrossRefPubMed
20.
Naz SM, Symmons DP: Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:871–883.CrossRefPubMed
21.
Toyoshima H, Kusaba T, Yamaguchi M: [Cause of death in autopsied RA patients]. Ryumachi 1993, 33:209–214.PubMed
22.
Leslie KO, Trahan S, Gruden J: Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007, 28:369–378.CrossRefPubMed
23.
Lee HK, Kim DS, Yoo B, et al.: Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005, 127:2019–2027.CrossRefPubMed
24.
Brusselle G: Rheumatoid arthritis and interstitial lung disease: a dangerous liaison. Rheumatology (Oxford) 2010 Mar 11 (Epub ahead of print).
25.
• Kim EJ, Collard HR, King TE Jr: Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009, 136:1397–1405. This article focuses on the relationship between HRCT findings and histologic subtype of RA-ILD. Based on this correlation between radiographic abnormalities and histopathology, the authors propose an algorithm for screening and monitoring of RA-ILD.CrossRefPubMed
26.
Yoshinouchi T, Ohtsuki Y, Fujita J, et al.: Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005, 26:121–125.CrossRefPubMed
27.
• Marten K, Dicken V, Kneitz C, et al.: Computer-assisted quantification of interstitial lung disease associated with rheumatoid arthritis: preliminary technical validation. Eur J Radiol 2009, 72:278–283. In this interesting analysis, the authors used computerized quantification of HRCT abnormalities to demonstrate correlations with pulmonary function parameters that include D L CO and FVC.CrossRefPubMed
28.
Rajasekaran A, Shovlin D, Saravanan V, et al.: Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 2006, 33:1250–1253.PubMed
29.
Park JH, Kim DS, Park IN, et al.: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705–711.CrossRefPubMed
30.
Klareskog L, Stolt P, Lundberg K, et al.: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38–46.CrossRefPubMed
31.
Nijenhuis S, Zendman AJ, Vossenaar ER, et al.: Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004, 350:17–34.CrossRefPubMed
32.
Makrygiannakis D, Hermansson M, Ulfgren AK, et al.: Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67:1488–1492.CrossRefPubMed
33.
Bongartz T, Cantaert T, Atkins SR, et al.: Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:70–75.CrossRef
34.
Alexiou I, Germenis A, Koutroumpas A, et al.: Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:511–513.CrossRefPubMed
35.
Inui N, Enomoto N, Suda T, et al.: Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem 2008, 41:1074–1077.CrossRefPubMed
36.
Bringardner BD, Baran CP, Eubank TD, Marsh CB: The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal 2008, 10:287–301.CrossRefPubMed
37.
Wilson MS, Wynn TA: Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009, 2:103–121.CrossRefPubMed
38.
Pardo A, Gibson K, Cisneros J, et al.: Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005, 2:e251.CrossRefPubMed
39.
Agostini C, Gurrieri C: Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006, 3:357–363.CrossRefPubMed
40.
Rao RN, Goodman LR, Tomashefski JF Jr: Smoking-related interstitial lung disease. Ann Diagn Pathol 2008, 12:445–457.CrossRefPubMed
41.
Saag KG, Kolluri S, Koehnke RK, et al.: Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996, 39:1711–1719.CrossRefPubMed
42.
Thorley AJ, Tetley TD: Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007, 2:409–428.PubMed
43.
Yang Q, Underwood MJ, Hsin MK, et al.: Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development. Curr Drug Metab 2008, 9:661–667.CrossRefPubMed
44.
Rosas IO, Richards TJ, Konishi K, et al.: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008, 5:e93.CrossRefPubMed
45.
Kinoshita F, Hamano H, Harada H, et al.: Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med 2004, 98:1131–1137.CrossRefPubMed
46.
Oyama T, Kohno N, Yokoyama A, et al.: Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung 1997, 175:379–385.CrossRefPubMed
47.
Saketkoo LA, Espinoza LR: Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med 2008, 168:1718–1719.CrossRefPubMed
48.
Afeltra A, Zennaro D, Garzia P, et al.: Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006, 35:388–394.CrossRefPubMed
Metadata
Title
Interstitial Lung Disease in Rheumatoid Arthritis
Author
Dana P. Ascherman
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 5/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0116-z

Other articles of this Issue 5/2010

Current Rheumatology Reports 5/2010 Go to the issue

ReviewPaper

Update on Biologic Therapy in the Management of Axial Spondyloarthritis

ReviewPaper

Remarkable Polymorphism of HLA-B27: An Ongoing Saga

CLINICAL TRIAL REPORT

HLA-B27 Homozygosity and Clinical Features of Ankylosing Spondylitis

ReviewPaper

Biomarkers in Spondyloarthritis

ReviewPaper

Regulation of Peripheral Inflammation by the Central Nervous System

ReviewPaper

Remission in Rheumatoid Arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits